Cargando…

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Primary refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) is an unresolved issue for DLBCL treatment and new treatments to overcome resistance is required. To explore the genetic mechanisms underlying treatment resistance in rrDLBCL and to identify candidate genes, we performed targeted de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Boram, Lee, Hyunwoo, Cho, Junhun, Yoon, Sang Eun, Kim, Seok Jin, Park, Woong-Yang, Kim, Won Seog, Ko, Young Hyeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992425/ https://www.ncbi.nlm.nih.gov/pubmed/33777778 http://dx.doi.org/10.3389/fonc.2021.628807

Ejemplares similares

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma
por: Jeong, Sun Young, et al.
Publicado: (2023)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
por: Cho, Junhun, et al.
Publicado: (2022)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

Clonal relationships in recurrent B-cell lymphomas
por: Lee, Seung Eun, et al.
Publicado: (2016)

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
por: Cho, Junhun, et al.
Publicado: (2021)

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
por: Kim, Seok Jin, et al.
Publicado: (2023)

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
por: Park, Ha Young, et al.
Publicado: (2016)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Metabolic activity of extranodal NK/T cell lymphoma on (18)F-FDG PET/CT according to immune subtyping
por: Lim, Chae Hong, et al.
Publicado: (2021)

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
por: Melchardt, Thomas, et al.
Publicado: (2016)

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
por: Lee, Hyunjee, et al.
Publicado: (2023)

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma
por: Lee, Ji Yun, et al.
Publicado: (2021)

Differences in mutational signature of diffuse large B‐cell lymphomas according to the primary organ
por: Koh, Hyun‐Hee, et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
por: Yang, Qing-Ming, et al.
Publicado: (2014)

Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2022)

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2023)

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma
por: Kang, Jin Hyun, et al.
Publicado: (2021)

Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis
por: Lee, Yong-Pyo, et al.
Publicado: (2022)

Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma
por: Ryu, Kyung Ju, et al.
Publicado: (2020)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)

Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2020)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
por: Cho, Inju, et al.
Publicado: (2020)

Relapsed/refractory diffuse large B cell lymphoma with cardiac involvement: A case report and literature review
por: Yang, Yuanyuan, et al.
Publicado: (2023)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2021)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma
por: Ryu, Kyung Ju, et al.
Publicado: (2016)

Indolent CD56-Positive Clonal T-Cell Lymphoproliferative Disease of the Stomach Mimicking Lymphomatoid Gastropathy
por: Hong, Mineui, et al.
Publicado: (2014)

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
por: Messori, Andrea, et al.
Publicado: (2022)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma
por: Maeng, Chi Hoon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3le62qbog63ie4apbt30p1esc7